Less than a tenth of individuals that would benefit from weight-loss injections such as Wegovy are able to get them, warns the WHO as it publishes its initial guidance on the drugs.
Given in excess of 1,000,000,000 people worldwide now classified as obese, it is calling for increased and just availability to GLP-1 medication.
Based on forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"The new guidance affirms that obesity is a lifelong illness that can be addressed with holistic and ongoing support," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are significant barriers to broad availability to the jabs that can help people shift significant body mass, explains the organization.
GLP-1 Therapy Shortage
Even in the present best projected outlook, the manufacturing of these medications might only reach approximately 100 million people – less than 10% of eligible patients, according to the WHO.
The recommendation encourages nations and manufacturers to expand access, via strategies including voluntary licensing.
A patent on semaglutide – the main component of Novo Nordisk's Wegovy – is scheduled to end in multiple nations in 2026.
How Obesity Jabs Work
GLP-1 drugs imitate a natural hormone to slow digestion, reduce hunger and boost the sense of being full so users reduce food intake.
Patients usually start to lose weight within a few weeks of beginning the regular doses.
Evidence indicates users may regain a significant portion within a year of stopping the drug, because their normal appetite return.
Being carrying excess weight raises your chance for contracting diseases, like type 2 diabetes, heart disease, brain attack, and specific cancers.
Excess weight impacts individuals in every country and was linked to millions of deaths worldwide in 2024, per the WHO.
